Belt and Road Weekly Investor Intelligence #6

Posted by Reading Time: 2 minutes

Welcome to this week’s issue of China Briefing’s Belt & Road Initiative Weekly Investor Intelligence round up.

As COVID-19 vaccines start to come to market, we look at the two different types of vaccines that are being developed, their pros and cons, and where across Asia distribution will commence and when.        

Special Report: COVID-19 2021 Vaccine Distribution Across Asia

We provide details of 40 countries in Asia and their plans for domestic COVID-19 vaccination distribution.

China’s COVID-19 Vaccine Development and Availability

China’s COVID-19 vaccines are expected to be rolled out soon; bulk manufactured and exported in 2021. China could likely mass inoculate citizens in any outbreak that crosses a certain threshold; the country is expected to develop herd immunity over longer term. The Sinovac vaccine (in limited roll-out) costs RMB 400.

COVID-19 Vaccine Roll Outs in ASEAN & Asia – Live Updates by Country

Details of COVID-19 vaccine development in all 10 ASEAN countries.

India COVID-19 Vaccine Development and Availability

The Indian Government is partnering with Russian, British and domestic firms for vaccine production, with a two shot treatment to be available from January 2021. Competitive consumer pricing agreed with BRICS nations.

About Us

Dezan Shira & Associates provide business intelligence, market research, legal, tax and compliance issues for foreign investors throughout Asia, and have 28 offices across the region. We are members of the Leading Edge Alliance, a network of related firms with offices throughout the world. For assistance with Belt & Road Initiative research, please contact us at silkroad@dezshira.com or visit us at www.dezshira.com. To subscribe to our Belt & Road Initiative portal, please click here.